Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilder, B. J.
Right arrow Articles by Villarreal, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilder, B. J.
Right arrow Articles by Villarreal, H. J.
NEUROLOGY 1978;28:892
© 1978 American Academy of Neurology

Valproic acid Interaction with other anticonvulsant drugs

B. J. Wilder, M.D., L. J. Willmore, M.D., J. Bruni, M.D. and H. J. Villarreal, M.D.

Neurology Service, Veterans Administration Hospital; the Department of Neurology, University of Florida; and the College of Medicine, Gainesville, Florida.

The interaction of valproic acid and other antiepileptic drugs was studied in 25 patients for 5 to 9 months. Clinical evaluations, seizure records, and antiepileptic drug levels were followed regularly. Eleven of the 13 patients required a reduced phenobarbital dose when concurrently treated with valproic acid. This reduction was prompted by sedation. An average dose reduction of 46 percent resulted in an average serum phenobarbital decrease of 15 percent. Ten of 15 patients had decreased phenytoin concentrations during concurrent administration with valproic acid. No definitive conclusion was reached about other antiepileptic drugs. Decreased phenobarbital excretion because of urine acidification and displacement of phenytoin from protein binding sites may account for the observations. Careful monitoring of anticonvulsant levels is required in anticipation of the documented interactions.

Reprint requests should be addressed to B. J. Wilder, M.D., Chief, Neurology Service, Veterans Administration Hospital, Gainesville. FL 32602.

This work was supported by the Medical Research Service of the Veterans Administration and the Epilepsy Research Foundation of Florida, Inc. Dr. Bruni is sponsored by the Ministry of Health, Ontario, Canada. Dr. Villarreal is sponsored by ANUIES, Mexico City, Mexico, and the Epilepsy Research Foundation of Florida, Inc.

Accepted for publication April 10, 1978.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by AAN Enterprises, Inc.